Biolegend, 652402, Purified anti-mouse Ki-67 Antibody, 100μg

The nuclear protein Ki-67 was first identified by the monoclonal antibody Ki-67, which was generated by immunizing mice with nuclei of the L428 Hodgkin lymphoma cell line. Ki-67 protein plays an essential role in ribosomal RNA transcription and cell proliferation. Expression of Ki-67 occurs during G1, S, G2, and M phase, while in G0 phase the Ki-67 protein is not detectable. Ki-67 is strongly expressed in proliferating cells and has been reported as a prognostic marker in various tumors.
100μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli expressed partial mouse Ki-67 recombinant protein, 1816-2163 aa.
Formulation: This antibody is provided in phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.Previous lots of this product may have been formulated with 0.1% or 0.05% NaN3 instead of 0.09% NaN3. For further information please contact BioLegend Technical Support or Customer Service.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: Upon receipt, store undiluted between 2°C and 8°C.
Application: ICFC - Quality tested WB, ICC, IHC-F - Verified
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume. For western blotting, suggested working dilution(s): Use 5 µl per 5 ml antibody dilution buffer for each mini-gel (0.5 µg/ml). For immunocytochemistry, a concentration range of 1.25 - 5.0 μg/mL is recommended. For immunohistochemistry on frozen tissue sections, a concentration range of 2.5 - 10.0 µg/mL is suggested. Additionally, each lot of this antibody is quality control tested by our Ki-67 staining protocol below. It is recommended that the reagent be titrated for optimal performance for each application.
Application References(PubMed link indicates BioLegend citation): Medina-Reyes EI, et al. 2015. Environ Res. 136:424. PubMed Guillaumond F, et al. 2015. PNAS. 112:2473. PubMed Sharma SK, et al. 2015. J Immunol. 194:5529. PubMed Rodero MP, et al. 2014. J. Invest. Dermatol. 7:1991-7. PubMed
Product Citations: Arnold IC, et al. 2019. PLoS Pathog. 15:e1007866. PubMed Minamide K, et al. 2020. Sci Rep. 10:14639. PubMed Bahreini F, et al. 2022. Bio Protoc. 12:e4414. PubMed Hirose W, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:153. PubMed Straß S, et al. 2023. Inflammopharmacology. 31:799. PubMed Gouirand V, et al. 2022. EMBO J. 41:e110466. PubMed Bahreini F, et al. 2022. Bio Protoc. 12: . PubMed Mugarza E, et al. 2022. Sci Adv. 8:eabm8780. PubMed Stewart CE, et al. 2022. Cancers (Basel). 14: . PubMed Herring CA et al. 2017. Cell systems. 6(1):37-51 . PubMed Xu L, et al. 2017. Int J Biol Macromol. . 10.1016/j.ijbiomac.2017.07.090. PubMed von Klitzing E, et al. 2018. Sci Rep. 20:594. PubMed Medina-Reyes E, et al. 2015. Environ Res. 136:424. PubMed Yuan CL, et al. 2018. Exp Ther Med. 9:1420. PubMed Heimesaat MM, et al. 2018. Eur J Microbiol Immunol (Bp). 1864:1609. PubMed Zingg D et al. 2018. Cancer cell. 34(1):69-84 . PubMed Mayer KA, et al. 2021. FASEB J. 35:e21217. PubMed Zappasodi R, et al. 2021. Nature. 591:652. PubMed Marable SS, et al. 2020. J Am Soc Nephrol. 2543:31. PubMed Brown EM, et al. 2019. Cell Host Microbe. 25:668. PubMed Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed Matsumoto Y, et al. 2019. Sci Rep. 9:15244. PubMed Zhao L, et al. 2018. Nat Med. 24:1536. PubMed Javary J, et al. 2021. Liver Int. 41:1423. PubMed Hallam D, et al. 2015. Exp Gerontol. 67: 72-79. PubMed Hsiao CC, et al. 2021. Cells. 10:. PubMed Horiuchi S, et al. 2021. Sci Immunol. :eabm3131. PubMed Guillaumond F, et al. 2015. Proc Natl Acad Sci U S A. 112:2473. PubMed Wang C, et al. 2016. J Cell Biol. 212: 545-60. PubMed Hollinshead KER, et al. 2020. Cell Rep. 33:108231. PubMed Rore H, et al. 2021. Commun Biol. 4:802. PubMed Johnson SA, et al. 2021. Eur J Immunol. 51:3228. PubMed Villarreal-Ponce A, et al. 2020. Cell Rep. 33:108417. PubMed Clark K, et al. 2019. Front Immunol. 10:2355. PubMed Men L, et al. 2018. Cell Physiol Biochem. 51:2185. PubMed Heimesaat MM, et al. 2019. Front Immunol. 10:49. PubMed Lkhagvadorj K, et al. 2020. Am J Physiol Lung Cell Mol Physiol. 319:L742. PubMed Miller AJ, et al. 2020. Dev Cell. 117:53. PubMed Klose A, et al. 2018. JCSM Rapid Commun. 9:20222. PubMed Scortegagna M, et al. 2020. Nat Commun. 11:99. PubMed Wang G, et al. 2019. Front Immunol. 1.380555556. PubMed Stelekati E, et al. 2018. Cell Rep. 2.445833333. PubMed Matsumori T, et al. 2020. Cancer Res. 80:5305. PubMed Madouri F, et al. 2017. J Allergy Clin Immunol. 139:1650. PubMed Maier B, et al. 2020. Nature. 580:257. PubMed Hennchen M, et al. 2015. J Neurosci. 35: 16531 - 16544. PubMed Lee J, et al. 2019. Yonsei Med J. 60:667. PubMed Chen M, et al. 2018. Am J Physiol Endocrinol Metab. 315:E72. PubMed
RRID: AB_11203533 (BioLegend Cat. No. 652401) AB_11204254 (BioLegend Cat. No. 652402)
Structure: 325 kD protein containing a forkhead-associated domain (FHA) and 13 tandem repeats
Distribution: Nucleus and chromosome
Function: Required for cell cycle progression and proliferation
Interaction: Interacts with KIF15; binds to MKI67IP through FHA domain
Biology Area: Cell Biology, Cell Cycle/DNA Replication, Transcription Factors
Molecular Family: Nuclear Markers
Antigen References: 1. Starborg M, et al. 1996. J. Cell. Sci. 109:143. 2. Byeon IJ, et al. 2005. Nat. Struct. Mol. Biol. 12:987. 3. Yerushalmi R, et al. 2010. Lancet. Oncol. 11:174. 4. Beltrami AP, et al. 2001. N. Engl. J. Med. 344:1750. 5. Sachsenberg N, et al. 1998. J. Exp. Med. 187:1295. 6. Nagy Z, et al. 1997. Acta. Neuropathol. 93:294.
Gene ID: 17345
UniProt: View information about Ki-67 on UniProt.org
Clone: 16A8
Regulatory Status: RUO
Other Names: KIA, proliferation-related Ki-67 antigen
Isotype: Rat IgG2a, κ